Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;70(11):3349-3355.
doi: 10.1007/s00262-021-02965-w. Epub 2021 May 18.

Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma

Affiliations

Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma

Beatrice Dozin et al. Cancer Immunol Immunother. 2021 Nov.

Abstract

Backgound: Literature reports suggest that the host immune system may control Malignant Pleural Mesothelioma (MPM) growth, although its activity is limited by regulatory mechanisms. In this retrospective study, we analyzed the levels of pro-inflammatory (IL-1, IL-6, TNF), immune-regulatory (IL-10) and Th1/CTL-related cytokines (IL-12p70, IFN-γ) in the pleural exudate and their relationship with overall survival (OS) in MPM.

Methods: Cytokines were quantified by multiplexed immunoassay. Concentrations were dichotomized with respect to the median value. Correlation between cytokine level and OS was assessed using univariate (Kaplan-Meier curves) and multivariate (Cox regression) analyses.

Results: Regarding outcome, tumor histology, therapies undergone and IFN-γ were independent prognostic factors of OS in a 72 MPM training cohort. Notably, high concentrations of IFN-γ halved death probability (HR of high vs low IFN-γ concentration = 0.491, 95%CI 0.3-0.8, p = 0.007). Also in patients with epithelioid histology and those receiving at least one line of therapy, high IFN-γ level was an independent factor predictive of OS (HR of high vs low IFN-γ concentration were 0.497, p = 0.007 and 0.324, p = 0.006, respectively). However, these data were not confirmed in a 77 MPM validation cohort, possibly due to the low IFN-γ levels encountered in this population, and the heterogeneous distribution of disease stages between the training and the validation cohorts. None of the other cytokines showed any effect on survival.

Conclusions: High level of IFN-γ in pleural effusion may be associated with better survival in MPM patients and potentially serve as a prognostic biomarker. Larger prospective studies are needed to ascertain this hypothesis.

Keywords: Biomarker; Immune response; Interferon-gamma; Mesothelioma; Outcome; Pleural effusion.

PubMed Disclaimer

Conflict of interest statement

The author declares there is no conflict of interest.

Figures

Fig. 1
Fig. 1
Levels of each cytokine in pleural effusion. The concentrations, in pg/ml, of IFN-γ, IL-10, IL-12p70, IL-1, TNF and IL-6 in pleural effusions of MPM patients are shown. Both training a and validation cohorts b are displayed. Right panels show the ratio values of IL-10/IL-12, used to define regulatory macrophages. Bars indicate median values
Fig. 2
Fig. 2
Kaplan–Meier survival curves according to IFN-γ concentration (as dichotomized around the median value of 13.8 pg/ml) in the whole population
Fig. 3
Fig. 3
Kaplan–Meier survival curves according to IFN-γ concentration (as dichotomized around the median value of 13.8 pg/ml) in the subgroup of patients with epithelioid histotype a and the subgroup of patients undergoing at least one line of therapy b. The insets report the HR values for IFN-γ (as > 13.8 pg/ml vs ≤ 13.8 pg/ml) obtained in multivariate Cox regressions including in a gender, tumor stage, ECOG score, therapy undergone and IFN-γ concentration; in b gender, histology, tumor stage, ECOG score and IFN-γ concentration

Similar articles

Cited by

References

    1. Carbone M, Adusumilli PS, Alexander HR, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69:402–429. doi: 10.3322/caac.21572. - DOI - PMC - PubMed
    1. de Gooijer CJ, Borm FJ, Scherpereel A, Baas P. Immunotherapy in malignant pleural mesothelioma. Front Oncol. 2020;10:187. doi: 10.3389/fonc.2020.00187. - DOI - PMC - PubMed
    1. Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18:1261–1273. doi: 10.1016/S1470-2045(17)30446-1. - DOI - PubMed
    1. Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20:239–253. doi: 10.1016/S1470-2045(18)30765-4. - DOI - PubMed
    1. Okada M, Kijima T, Aoe K, et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, japanese phase ii study in malignant pleural mesothelioma (MERIT) Clin Cancer Res. 2019;25:5485–5492. doi: 10.1158/1078-0432.CCR-19-0103. - DOI - PubMed

LinkOut - more resources